Categorynews

GlycoMimetics to Present at Upcoming Investor Conferences

April 4, 2019 Off By BusinessWire

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior
management will present corporate updates at two upcoming investor
conferences in April. Details are as follows:

HC WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
Who: Chief
Financial Officer Brian Hahn
When: Tuesday, April 9 at
2:10 p.m. (GMT)
Where: London, UK

18^TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Who:
Chief Executive Officer Rachel King
When: Wednesday,
April 10 at 3:30 p.m. (ET)
Where: New York, NY

To access the live webcast and subsequent archived recordings for each
of these presentations, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics’ most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics’ wholly owned drug candidate,
uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is being evaluated
across a range of patient populations including a company-sponsored
Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also
completed a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.